Search

Victor D Gurewich

from Cambridge, MA
Age ~95
Get Report
Also known as:
Vic Gurewich
Phone and address:
11 Reservoir St, Cambridge, MA 02138
(617) 497-7336
Related to:
Jane Czuppa
Connected to:
Lance W Gurewitz, 32Abdi O Gurey, 74Dennise Gurfinkiel, 38Joshua H Gurganious, 40Dean J Gurganus, 70Jana L Gurganus, 54Kristine J Gurganus, 51Margie D Gurganus, 76Rod Gurganus, 60Claudia C Gurgel, 58

Victor Gurewich Phones & Addresses

  • 11 Reservoir St, Cambridge, MA 02138 (617) 497-7336 (617) 497-7328
  • 300 Mount Auburn St, Cambridge, MA 02138 (617) 661-0567
  • 300 Mount Auburn St #409, Cambridge, MA 02138 (617) 497-7328
  • Boston, MA
  • 11 Reservoir St, Cambridge, MA 02138 (617) 497-7336

Work

Company: Victor Gurewich MD Address: 300 Mount Auburn St Suite 305, Cambridge, MA 02138 Phones: (617) 661-0567

Education

School / High School: Harvard Medical School 1955

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 1962

Specialities

Internal Medicine

Professional Records

Medicine Doctors

Victor Gurewich Photo 1

Dr. Victor Gurewich, Cambridge MA - MD (Doctor of Medicine)

View page
Specialties:
Internal Medicine
Address:
Victor Gurewich MD
300 Mount Auburn St Suite 305, Cambridge, MA 02138
(617) 661-0567 (Phone)
Certifications:
Internal Medicine, 1962
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Victor Gurewich MD
300 Mount Auburn St Suite 305, Cambridge, MA 02138

Mount Auburn Hospital
330 Mount Auburn Street, Cambridge, MA 02138
Education:
Medical School
Harvard Medical School
Graduated: 1955
Medical School
Beth Israel Deaconess Medical Center
Graduated: 1955
Medical School
West Roxbury Va Hosp
Graduated: 1955
Medical School
West Roxbury Va Hospital
Graduated: 1955
Victor Gurewich Photo 2

Victor Gurewich

View page
Specialties:
Internal Medicine, Vascular Medicine
Work:
Victor Gurewich MD
300 Mt Auburn St STE 305, Cambridge, MA 02138
(617) 661-0567 (phone), (617) 876-0524 (fax)
Education:
Medical School
Harvard Medical School
Graduated: 1955
Procedures:
Electrocardiogram (EKG or ECG)
Vaccine Administration
Conditions:
Abdominal Hernia
Anemia
Anxiety Phobic Disorders
Atrial Fibrillation and Atrial Flutter
Benign Prostatic Hypertrophy
Languages:
English
French
German
Description:
Dr. Gurewich graduated from the Harvard Medical School in 1955. He works in Cambridge, MA and specializes in Internal Medicine and Vascular Medicine. Dr. Gurewich is affiliated with Mount Auburn Hospital.
Victor Gurewich Photo 3

Victor Gurewich, Cambridge MA

View page
Specialties:
Internist
Address:
300 Mount Auburn St, Cambridge, MA 02138
Education:
Harvard Medical School - Doctor of Medicine
West Roxbury VA Medical Center - Residency - Cardiology
Beth Israel Deaconess Medical Center - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine

Resumes

Resumes

Victor Gurewich Photo 4

Professor Of Medicine, Harvard Medical School

View page
Location:
Boston, MA
Industry:
Hospital & Health Care
Work:
Beth Israel Deaconess Medical Center
Professor of Medicine, Harvard Medical School
Victor Gurewich Photo 5

Chief Scientific Officer

View page
Location:
Cambridge, MA
Industry:
Biotechnology
Work:
Thrombolytic Science International
Chief Scientific Officer
Victor Gurewich Photo 6

Physician, Professor Of Medicine

View page
Location:
Cambridge, MA
Industry:
Biotechnology
Work:

Physician, Professor of Medicine
Thrombolytic Science
Physician, Professor of Medicine, Harvard Medical School

Business Records

Name / Title
Company / Classification
Phones & Addresses
Victor Gurewich
Owner, Internal Medicine, Medical Doctor
Victor Gurewich Md
Medical Practice · Medical Doctor's Office
300 Mt Auburn St #305, Cambridge, MA 02138
(617) 661-0567
Victor Gurewich
Dr. Victor Gurewich
Family Doctor
300 Mt Auburn, Cambridge, MA 02138
(617) 661-0567
Victor Gurewich
Mbr
Thrombolytic Science
Biotechnology · Mfg Pharmaceutical Preparations
763D Concord Ave, Cambridge, MA 02138
763 Concord Ave, Cambridge, MA 02138
(617) 661-1103
Victor Gurewich
President
VASCULAR LABORATORY, INC
Nonclassifiable Establishments · Noncommercial Research Organization
B.i Deaconess Medical Ctr 1 Deaconess Rd, Boston, MA 02215
763 Concord Ave, Cambridge, MA 02138
763D Concord Ave, Cambridge, MA 02138
(617) 632-0801, (617) 661-1103

Publications

Us Patents

Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots

View page
US Patent:
7074401, Jul 11, 2006
Filed:
Apr 16, 2004
Appl. No.:
10/826826
Inventors:
Victor Gurewich - Cambridge MA, US
John N. Williams - Boston MA, US
Jian-Ning Liu - Brighton MA, US
Paolo Sarmientos - Lecco, IT
Massimiliano Pagani - Castelli Calepio, IT
Assignee:
Thrombolytic Science, Inc. - Boston MA
International Classification:
A61K 38/49
A61K 38/36
C12N 9/72
C12N 9/64
C07H 21/04
US Classification:
424 9463, 435215, 435226, 514 12, 536 232
Abstract:
It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys→His), perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e. g. , after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

C-1 Inhibitor Prevents Non-Specific Plasminogen Activation By A Prourokinase Mutant Without Impeding Fibrin-Specific Fibrinolysis

View page
US Patent:
7837992, Nov 23, 2010
Filed:
Apr 4, 2007
Appl. No.:
11/732620
Inventors:
Victor Gurewich - Cambridge MA, US
Ralph Pannell - Brighton MA, US
Assignee:
Beth Israel Deaconess Medical Center - Boston MA
International Classification:
A61K 38/48
C12N 9/72
C12N 9/68
US Classification:
424 9464, 435215, 435217
Abstract:
A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5 with supplemental C1-inhibitor showed no attenuation of the rate of fibrinolysis, whereas fibrinogenolysis was prevented by C1-inhibitor. Due to higher dose tolerance of M5 with C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis without inhibitor. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 and thereby non-specific plasminogen activation. At the same time, fibrin-specific plasminogen activation remained unimpaired. This unusual dissociation of effects has significant implications for improving the safety and efficacy of fibrinolysis.

C1-Inhibitor Prevents Non-Specific Plasminogen Activation By A Prourokinase Mutant Without Impeding Fibrin-Specific Fibrinolysis

View page
US Patent:
8187592, May 29, 2012
Filed:
Nov 16, 2010
Appl. No.:
12/947573
Inventors:
Victor Gurewich - Cambridge MA, US
Ralph Pannell - Brighton MA, US
Assignee:
Thrombolytic Science, LLC - Cambridge MA
International Classification:
C12N 9/72
C12N 9/68
A61K 38/48
US Classification:
424 9464, 435415, 435417
Abstract:
A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5 with supplemental C1-inhibitor showed no attenuation of the rate of fibrinolysis, whereas fibrinogenolysis was prevented by C1-inhibitor. Due to higher dose tolerance of M5 with C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis without inhibitor. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 and thereby non-specific plasminogen activation. At the same time, fibrin-specific plasminogen activation remained unimpaired. This unusual dissociation of effects has significant implications for improving the safety and efficacy of fibrinolysis.

Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots

View page
US Patent:
20070148160, Jun 28, 2007
Filed:
Jun 6, 2006
Appl. No.:
11/447455
Inventors:
Victor Gurewich - Cambridge MA, US
Jian-Ning Liu - Newton MA, US
Paolo Sarmientos - Lecco, IT
Assignee:
Thrombolytic Science, Inc. - Cambridge MA
International Classification:
A61K 38/48
US Classification:
424094640
Abstract:
It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

C-1 Inhibitor Prevents Non-Specific Plasminogen Activation By A Prourokinase Mutant Without Impeding Fibrin-Specific Fibrinolysis

View page
US Patent:
20090010916, Jan 8, 2009
Filed:
Jul 1, 2008
Appl. No.:
12/215966
Inventors:
Victor Gurewich - Cambridge MA, US
Ralph Pannell - Brighton MA, US
International Classification:
A61K 38/49
A61P 7/00
US Classification:
424 9463
Abstract:
A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous conversion to tcuPA in blood at therapeutic concentrations. Two-chain M5 was shown to form complexes with C1-inhibitor, which was the principal inhibitor of tcM5 in plasma. The effect of supplemental additions of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restored the stability of high-dose M5 and prevented fibrinogenolysis but not fibrinolysis, the rate of which was not compromised by the inhibitor. Due to higher dose tolerance of M5 in the presence of supplemental C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis, which is the maximum possible for a plasminogen activator. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 which would otherwise greatly amplify non-specific plasminogen activation causing more tcM5 generation from M5. This unusual dissociation of inhibitory effects, whereby fibrinogenolysis and not fibrinolysis is inhibited, has significant implications for improving the safety and efficacy of fibrinolysis. Methods of reducing bleeding and non-specific plasminogen activation during fibrinolysis by administering M5 along with exogenous C1-inhibitor are disclosed.

Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots

View page
US Patent:
20090136557, May 28, 2009
Filed:
Aug 7, 2008
Appl. No.:
12/187807
Inventors:
Victor Gurewich - Cambridge MA, US
Jian-Ning Liu - Brighton MA, US
Paolo Sarmientos - Milano, IT
International Classification:
A61F 2/02
A61K 38/48
US Classification:
424423, 424 9463
Abstract:
It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots

View page
US Patent:
20090226410, Sep 10, 2009
Filed:
Jun 30, 2008
Appl. No.:
12/165082
Inventors:
Victor Gurewich - Cambridge MA, US
Jian-Ning Liu - Brighton MA, US
Paolo Sarmientos - Milano, IT
International Classification:
A61K 38/45
A61P 9/00
US Classification:
424 945
Abstract:
It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots

View page
US Patent:
20090226413, Sep 10, 2009
Filed:
Jul 1, 2008
Appl. No.:
12/165904
Inventors:
Victor GUREWICH - Cambridge MA, US
Jian-Ning LIU - Brighton MA, US
Paolo SARMIENTOS - Milano, IT
International Classification:
A61K 38/49
C12N 9/72
C12Q 1/48
US Classification:
424 9464, 435215, 435 15
Abstract:
It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.
Control profile
Victor D Gurewich from Cambridge, MA, age ~95 Get Report